Esta web utiliza cookies para que podamos ofrecerte la mejor experiencia de usuario posible. La información de las cookies se almacena en tu navegador y realiza funciones tales como reconocerte cuando vuelves a nuestra web o ayudar a nuestro equipo a comprender qué secciones de la web encuentras más interesantes y útiles.
Publicaciones realizadas por los miembros de la Fundación.
Carreño V, Quiroga JA. J Hepatol 1995; 22: s122-s126.
Semiquantification by Amplicor TM assay of hepatitis C virus genome during therapy
Navas S,Carreño V. J Hepatol 1995; 22: s115-s117.
Ribozymes: structure, characteristics and use as potential antiviral agents
Bartolomé J, Madejón A,Carreño V. J Hepatol 1995; 22: s57-s64.
Hepatitis B and D genomes in hepatitis B surface antigen negative patients with chronic hepatitis C
González S, Navas S, Madejón A, Bartolomé J, Castillo I, Moraleda G, Martín J, Marriott E, Herrero M,Carreño V. J Med Virol 1995; 45: 168-173.
Analysis of hepatitis B virus precore variants in hepatitis B e antibody-positive patients treated with prednisone plus interferon.
López-Alcorocho JM, Cabrerizo M, Bartolomé J, Cotonat T,Carreño V. J Viral Hepatitis 1995; 2: 279-284.
Porphyria cutanea tarda and hepatitis C and B viruses infection: A retrospective study.
Navas S, Bosch O, Castillo I, Marriott E,Carreño V. Hepatology 1995; 21: 279-284.
ltimos avances en hepatología.
Carreño V, Bartolomé J, Castillo I.Hepatol Clin 1995; 3: 223-240.
Sequence of non-structural regions 3 and 5 of hepatitis C virus genomes from Spanish patients: existence of a predominant variant related to type 1b
Pernas M, Bartolomé J, Castillo I, Quiroga JA, Pardo M,Carreño V.J Gen Virol 1995; 76: 415-420.
Immunoglobulin M antibody to hepatitis C virus core antigen: Correlations with viral replication, histological activity and liver disease outcome.
Quiroga JA, van Binsbergen J, Wang CY, Pardo M, Navas S, Trines Ch, Herrero M,Carreño V. Hepatology 1995; 22: 1635-1640.
Hepatitis viral aguda
Carreño V, Quiroga JA. En: Tratado de Medicina Interna, Sección XI, Capítulo 5MDíaz Rubio, DEspinós EdsEditorial Panamericana, Madrid, 1994; 1384-1396
Long-term follow-up study of serum IgM antibody to hepatitis C virus (HCV), HCV replication and liver disease outcome in chronic hepatitis C.
Quiroga JA, Herrero M, Castillo I, Navas S, Pardo M,Carreño V. J Infect Dis 1994; 170: 669-673.
Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B
Thomas HC, Lok ASF,Carreño V, Farrell G, Tanno H, Pérez V, Dusheiko GM, Cooksley G, Ryff JC and the International Hepatitis Trial Group. J Viral Hepatitis 1994; 1: 139-148.
Analysis of hepatitis B precore region in serum and liver of chronic hepatitis B virus carriers
López-Alcorocho JM, Moraleda G, Bartolomé J, Castillo I, Cotonat T, Aguilar J, Ortega E, Pons JA, Salmerón J, Vázquez-Iglesias JL,Carreño V. J Hepatol 1994; 21: 353-360.
Lack of efficacy of inosine pranobex in the treatment of chronic hepatitis C
Pardo,Carreño V. J Hepatol 1994; 21: 278.
ltimos avances en hepatología.
Carreño V, Castillo I, Quiroga JA.Hepatol Clin 1994; 2: 275-308.
Hepatitis delta virus infection: Molecular biology and treatment.
Carreño V, Bartolomé J, Madejón A. Dig Dis 1994; 12: 265-275.
Positive and negative hepatitis C virus RNA strands in serum, liver and peripheral blood mononuclear cells in anti-HCV patients: Relation with the liver lesion.
Navas S, Castillo I, Bartolomé J, Marriott E, Herrero M,Carreño V. J Hepatol 1994; 21: 182-186.
Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to alpha-interferon
Quiroga JA, Martín J, Pardo M,Carreño V. Dig Dis Sci 1994; 39: 2485-2496.
Retreatment of chronic hepatitis C virus infection.
Pardo M, Cotonat T, Herrero M, Marriott E, Artillo S, Quiroga JA,Carreño V. Lancet 1994; 343: 1568-1569.
ltimos avances en hepatología.
Carreño V.Hepatol Clin 1994; 2: 201-228.